Get started
Author

Eleonora Cannas

Observed name: E. Cannas
ORCID: 0009-0000-9551-7122
Observed ORCID: 0009-0000-9551-7122
OpenAlex ID: A5041093024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy
2024 · Chiara Tarantelli, David Wald, et al. · Haematologica · 21
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
2023 · Alberto J. Arribas, Sara Napoli, et al. · Molecular Cancer Therapeutics · 21
PDF
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
2024 · Alberto J. Arribas, Sara Napoli, et al. · Blood Advances · 12
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas
2026 · Alberto J. Arribas, Eleonora Cannas, et al. · Blood · 11
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type
2021 · Chiara Tarantelli, Eleonora Cannas, et al. · Exploration of Targeted Anti-tumor Therapy · 8
PDF
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
2025 · Binu Kandathilparambil Sasi, Chiara Tarantelli, et al. · Haematologica · 6
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas
2025 · Chiara Tarantelli, Filippo Spriano, et al. · Cancers · 2
PDF
Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity
2024 · Filippo Spriano, Luciano Cascione, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
PDF
Abstract C139: The IRAK4 inhibitor emavusertib (CA-4948) synergizes with second generation BTK inhibitors acalabrutinib and zanubrutinib in MYD88-L265P mutated lymphoma cell lines
2023 · Francesca Guidetti, Alberto J. Arribas, et al. · Molecular Cancer Therapeutics · 2
CDK9 pharmacological inhibition with PRT2527 has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitors
2026 · Eleonora Cannas, Alberto J. Arribas, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models
2025 · Laura Barnabei, Alberto J. Arribas, et al. · SSRN Electronic Journal · 1
Abstract 7140: A new series of flavonoid derivatives with anti-cancer activity includes SDN207, SND210, SND524, and SND562 as potent microtubule-targeting agents
2024 · Alberto J. Arribas, Eleonora Cannas, et al. · Cancer Research · 1
Novel Pi3kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies
2023 · Binu Kandathilparambil Sasi, Chiara Tarantelli, et al. · Blood · 1
Abstract 394: ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
2023 · Alberto J. Arribas, Sara Napoli, et al. · Cancer Research · 1
Improving responses to dual PI3K/BCL2 inhibition in lymphomas: results of a pharmacological screen with over 1,400 compounds
2022 · A. Arribas, M. Chiappa, et al. · European Journal of Cancer · 1
PDF
Aberrant expression of HERV-K envelope in lymphoma represents an opportunity for novel treatments.
2026 · Filippo Spriano, Luciano Cascione, et al. · Molecular Cancer Therapeutics
Abstract A058: Clinical and preclinical evidence indicate gender-based differences in the sensitivity of B-cell lymphoid tumors to BTK inhibitors
2026 · Eleonora Cannas, Flaminia Facella, et al. · Blood Cancer Discovery
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma—SAKK 66/18 Trial
2026 · Maria Cristina Pirosa, Dagmar Hess, et al. · Cancers
Abstract 1848: IL-1-driven signaling promotes resistance to PI3K and BCL2 inhibitors in B-cell lymphoma preclinical models.
2026 · Alberto J. Arribas, Federica Fuzio, et al. · Cancer Research
Abstract 1849: Dual inhibition of AURKA and ERBB overcomes resistance to PI3K/BTK/BCL2 inhibitors in marginal zone lymphoma models.
2026 · Emma Pesenti, Alberto J. Arribas, et al. · Cancer Research
Abstract 7119: Large-scale drug screening identifies clinically actionable combinations to overcome BTK/PI3K inhibitor resistance in marginal zone lymphoma
2026 · Alberto J. Arribas, Elena Mariotto, et al. · Cancer Research
Abstract 1857: Mechanisms of acquired resistance to BTK and BCL2 inhibitors reveal clinically actionable vulnerabilities in B-cell lymphoma.
2026 · Alberto J. Arribas, Camilla Scalise, et al. · Cancer Research
Targeting Aberrant FGFR Signaling with Infigratinib Enhances the Efficacy of BTK/PI3K Inhibitors and Bendamustine in Lymphoma Cells
2025 · Giulio Sartori, Alessandro Ghiringhelli, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
A high‐throughput bone marrow 3D co‐culture system to study resistance to BCR signalling targeted agents in B‐ NHL
2025 · Alex Zadro, Alberto Arribas, et al. · British Journal of Haematology
PDF
High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone Lymphoma
2025 · Alex Zadro, Alberto Arribas, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Works count: 94
Citation count: 91
H-index: 6
I10-index: 4
Year
Topic
Type